[go: up one dir, main page]

SG165343A1 - Jnk inhibitors for the treatment of endometriosis - Google Patents

Jnk inhibitors for the treatment of endometriosis

Info

Publication number
SG165343A1
SG165343A1 SG201006416-0A SG2010064160A SG165343A1 SG 165343 A1 SG165343 A1 SG 165343A1 SG 2010064160 A SG2010064160 A SG 2010064160A SG 165343 A1 SG165343 A1 SG 165343A1
Authority
SG
Singapore
Prior art keywords
endometriosis
treatment
jnk inhibitors
jnk inhibitor
jnk
Prior art date
Application number
SG201006416-0A
Other languages
English (en)
Inventor
Stephen S Palmer
Selvaraj Nataraja
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SG165343A1 publication Critical patent/SG165343A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201006416-0A 2005-07-15 2006-07-12 Jnk inhibitors for the treatment of endometriosis SG165343A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69965805P 2005-07-15 2005-07-15
EP05109447 2005-10-11

Publications (1)

Publication Number Publication Date
SG165343A1 true SG165343A1 (en) 2010-10-28

Family

ID=35709133

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006416-0A SG165343A1 (en) 2005-07-15 2006-07-12 Jnk inhibitors for the treatment of endometriosis

Country Status (11)

Country Link
US (1) US8592414B2 (es)
EP (1) EP1904181A2 (es)
JP (1) JP2009509916A (es)
KR (1) KR20130087052A (es)
AU (1) AU2006270184B2 (es)
BR (1) BRPI0613042A2 (es)
CA (1) CA2611598A1 (es)
EA (1) EA016437B1 (es)
MX (1) MX2008000663A (es)
SG (1) SG165343A1 (es)
WO (1) WO2007011762A2 (es)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486469T2 (de) 1983-11-02 1999-04-15 Applied Research Systems Ars Holding N.V., Curacao Herstellung heterodimirer menschlicher Fruchtbarkeitshormone
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US4988679A (en) 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
GEP20002142B (en) 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
EP0727406B1 (de) 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
KR20010087421A (ko) 1998-12-17 2001-09-15 프리돌린 클라우스너, 롤란드 비. 보레르 4- 및 5-알키닐옥신돌과 4- 및 5-알케닐옥신돌
KR100723854B1 (ko) 1998-12-17 2007-05-31 에프. 호프만-라 로슈 아게 4,5-아졸로-옥신돌
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
CA2381882C (en) 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2001012609A1 (en) 1999-08-19 2001-02-22 Signal Pharmaceuticals, Inc. Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
WO2001062959A2 (en) * 2000-02-25 2001-08-30 Metriogene Biosciences Inc. Endometriosis-related markers and uses thereof
EP1193267A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
PT1450792E (pt) 2001-12-07 2006-12-29 Applied Research Systems Derivados de benzazole para o tratamento de esclerodermia
US7635681B2 (en) * 2002-01-09 2009-12-22 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
CA2478338A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
AU2003233067B2 (en) 2002-04-25 2009-01-08 Merck Serono Sa Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders
KR20050048642A (ko) 2002-09-25 2005-05-24 메이지 세이카 가부시키가이샤 서방성 농약 입제
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2004082665A1 (ja) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited 放出制御組成物
AU2004271740B2 (en) 2003-09-12 2010-10-28 Merck Serono Sa Benzothiazole derivatives for the treatment of diabetes
US20070079629A1 (en) 2003-10-30 2007-04-12 Laboratories Serono S.A. Process and apparatus for cooling and atomizing liquid or pasty-like substances
RU2253489C1 (ru) * 2004-04-07 2005-06-10 Научный центр акушерства, гинекологии и перинатологии РАМН Способ лечения бесплодия у женщин с наружным генитальным эндометриозом
US7838522B2 (en) * 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用

Also Published As

Publication number Publication date
CA2611598A1 (en) 2007-01-25
AU2006270184A1 (en) 2007-01-25
WO2007011762A3 (en) 2007-04-05
EP1904181A2 (en) 2008-04-02
WO2007011762A2 (en) 2007-01-25
US8592414B2 (en) 2013-11-26
EA200800343A1 (ru) 2008-06-30
BRPI0613042A2 (pt) 2010-12-14
JP2009509916A (ja) 2009-03-12
KR20130087052A (ko) 2013-08-05
US20090176761A1 (en) 2009-07-09
AU2006270184B2 (en) 2011-09-29
EA016437B1 (ru) 2012-05-30
WO2007011762A8 (en) 2007-08-02
MX2008000663A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
JO2886B1 (en) Useful compounds in the inhibition of CHK1
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY153669A (en) Ocular allergy treatments field of the invention
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
TW200605886A (en) Indazoles useful in treating cardiovascular diseases
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
TW200733976A (en) Method for the treatment of cognitive dysfunction
MXPA05011501A (es) Combinacion terapeutica de un inhibidor de cox-2 y un inhibidor de aromatasa.
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
TW200730190A (en) New combination to treat liver fibrosis
WO2009148600A3 (en) Deuterated lysine-based compounds
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
SG165343A1 (en) Jnk inhibitors for the treatment of endometriosis
WO2008063853A3 (en) Cancer treatment method
ZA200710497B (en) Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
TW200642688A (en) New use of PDE7 inhibitors
UA89242C2 (ru) Способ лечения эндометриоза с применением ингибитора jnk, которым является производное бензотиазола
NO20080782L (no) JNK-inhibitorer for behandling av endometriose
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors